Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02152696 · ClinicalTrials.gov registry record · Phase 3
Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location
A Phase 3 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 255
- Enrollment target
NCT02152696 is a Phase 3 study that has completed, run by Yale University. The registered enrollment target is 255 participants.
The verdict
NCT02152696, a Phase 3 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 255 participants
- Enrollment target
Study Summary
This is a randomized controlled trial to compare three currently available management strategies for women with a persisting pregnancy of unknown location (PPUL), which makes them at-risk for ectopic pregnancy. We will recruit hemodynamically stable women with a confirmed PPUL to be randomized to one of three strategies: 1) Uterine evacuation followed by methotrexate (MTX) for some (those that have evidence of a non visualized ectopic pregnancy) 2) Empiric treatment with MTX for all 3) Expectant management. Randomization will be 1:1:1 into these three arms. After randomization, they will be followed and treated clinically as is indicated by the progression of their condition. Primary outcome measures: uneventful decline of hCG to 5 IU/mL.
Interventions
- DRUG Methotrexate
- OTHER Expectant Management
- PROCEDURE Uterine Evacuation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2014-07-25 |
| Est. Completion | 2019-08-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02152696
The ClinicalTrials.gov registry entry for NCT02152696 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Methotrexate is the first listed.
NCT02152696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02152696 about?
NCT02152696 is a clinical study titled "Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location". This is a randomized controlled trial to compare three currently available management strategies for women with a persisting pregnancy of unknown location (PPUL), which makes them at-risk for ectopic pregnancy. We will recruit hemodynamically stable women with a confirmed PPUL to be randomized to on...
What is the current status of trial NCT02152696?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 255 participants. The study started on 2014-07-25. Estimated completion is 2019-08-19.
What interventions are being tested in trial NCT02152696?
The interventions under investigation include: Methotrexate (DRUG), Expectant Management (OTHER), Uterine Evacuation (PROCEDURE).
Who is sponsoring clinical trial NCT02152696?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.